Spectra Clinical Labs: The Verdict Followed by an Acquittal

Spectra Clinical Labs’ operator was acquitted on July 11, 2025, after a jury found him guilty on February 25, 2025. The Eastern District of Michigan granted judgment of acquittal on both counts, rejecting the prosecution’s kickback theory and finding insufficient evidence that the operator knew about unauthorized test orders. The acquittal supersedes the guilty verdict.

Spectra was a toxicology laboratory in Gardena, California, serving patients receiving pain-management treatment. The Justice Department’s verdict announcement described more than $4 million in Medicare payments for urine drug tests that prosecutors said doctors did not want or authorize. That announcement gives the prosecution’s account of the trial. The later court order explains why that account did not sustain the operator’s conviction.

What Happened Between the Verdict and the Acquittal?

The jury found the operator guilty of a kickback conspiracy and a conspiracy to commit health care fraud and wire fraud. He then asked the court to enter an acquittal because the evidence could not support those convictions. The court granted that request on both counts.

The ruling addressed two different questions. On the kickback count, the court rejected the government’s theory that paying marketers to obtain referrals from physicians, without more, established the charged violation. It also found insufficient evidence that the operator knew the payments were unlawful. On the fraud count, the missing connection was his knowledge of orders the physicians had not authorized.

Those conclusions changed the outcome. The story of the commissions and test orders remains part of the criminal case, but the court’s rejection of the charges against the operator belongs beside it.

Commissions Reached Into the Doctor’s Office

According to the Justice Department’s account of evidence presented at the criminal trial, Spectra’s owner paid marketers a percentage of Medicare reimbursements and routed the money through nominally independent marketing companies he secretly controlled. Prosecutors said the arrangement encouraged marketers to obtain orders for the highest-reimbursing urine drug-testing panels.

The department described the next step as staff training. Marketers allegedly taught staff members at doctors’ offices to send Spectra orders for medically unnecessary tests the doctors did not authorize. Prosecutors linked that conduct to both the laboratory’s profits and the marketers’ commissions.

The payment formula explains why the office workflow matters. In the government’s account, the people promoting the tests had a financial interest in the reimbursement those tests generated. Their work extended from persuading a practice to use Spectra into teaching staff what orders to send. A person who saw that training could describe a part of the alleged scheme that a Medicare payment entry would never explain.

When Are Toxicology Tests Unnecessary?

For Medicare billing, toxicology tests need a patient-specific medical reason and an order from the treating clinician. In the criminal case’s pretrial order, the court recorded prosecutors’ explanation that their case concerned tests never ordered, altered orders and office personnel induced to request tests physicians did not want. Their allegation went to who chose the testing, inside the practice, before a claim reached Medicare.

That is what makes the government’s Spectra account so pointed: it described a commercial incentive to obtain expensive panels while the treating doctors’ decisions were allegedly being bypassed. The later acquittal order records the operator’s concession that the evidence showed some unauthorized orders reached Medicare. The court nevertheless found insufficient evidence that he knew of them.

Why the Documentation Warnings Did Not Prove the Charged Fraud

The acquittal order distinguishes missing medical-necessity documentation from proof that the operator knew doctors had not authorized the tests. Prosecutors relied on Medicare contractor Noridian’s audits and compliance advice to establish his knowledge. The court found that those materials did not supply the connection the fraud charge required.

Noridian’s audits addressed inadequate documentation from the ordering providers. The court explained that notice of those deficiencies did not establish awareness of unauthorized orders. A private compliance officer’s general warning against false claims likewise did not show that she had told the operator Spectra was submitting such claims.

The order also addressed a later compliance letter about supporting records and testing frequency. The court found that the letter said nothing about tests physicians had not authorized. The court concluded that the government had not shown the operator knew Spectra was submitting unauthorized orders to Medicare.

This distinction matters to someone who saw the office workflow. A missing supporting record, a test added without permission and a manager’s knowledge of that addition are different parts of the account. In Spectra’s case, the court found that the prosecution had not connected them sufficiently to sustain the operator’s fraud conviction.

What Evidence Is Needed to Prove Fraud?

For an unauthorized-order allegation, the evidence needs to explain who made the testing decision and how the laboratory came to bill for it. Our whistleblower experts work through that connection with you. In the Spectra account, the alleged staff training and the marketers’ compensation explain why an office employee’s knowledge can matter as much as a billing record.

Different people see different parts of that sequence. A medical assistant may know how an order was prepared. A laboratory employee may know which testing was performed. Billing staff may see the claim, while someone on the marketing side knows how commissions were calculated. Someone working in healthcare sales may recognize the payment arrangement before anyone reviewing a claim sees how the order was obtained.

The marketing side has supplied whistleblowers in a separate civil case. Co-founders of a former third-party marketer brought the Admera Health case over commission payments. The company reached a $5,389,648 settlement of kickback allegations, announced on July 24, 2024. That case shows why someone outside the laboratory can still know the arrangement that brought it business.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Saw How the Orders Were Made

If you saw how marketers, clinic staff or laboratory billing turned sales instructions into test orders and claims, tell our whistleblower experts how it worked. We build your strongest laboratory fraud whistleblower case with you, bring in laboratory fraud whistleblower lawyers who understand health care billing, and stay beside you throughout the case.